Clinical trial
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030498 |
|---|---|
| Title | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| Official title | Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma and 77 more |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 75 |
| Start date | Dec 1, 2001 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: